Share This Page
Drug Price Trends for NDC 23155-0872
✉ Email this page to a colleague
Average Pharmacy Cost for 23155-0872
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| TORSEMIDE 10 MG TABLET | 23155-0872-01 | 0.07165 | EACH | 2025-11-19 |
| TORSEMIDE 10 MG TABLET | 23155-0872-01 | 0.07216 | EACH | 2025-10-22 |
| TORSEMIDE 10 MG TABLET | 23155-0872-01 | 0.07463 | EACH | 2025-09-17 |
| TORSEMIDE 10 MG TABLET | 23155-0872-01 | 0.07663 | EACH | 2025-08-20 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 23155-0872
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 23155-0872
Introduction
The pharmaceutical landscape continually evolves with new approvals, market entries, and competitive shifts. NDC 23155-0872 pertains to a specific pharmaceutical product registered within the National Drug Code (NDC) system. Precise details about this drug—such as its generic name, therapeutic class, manufacturer, and indications—are essential for comprehensive analysis, but this data appears to be proprietary or obscured in the query. Nevertheless, based on available market trends, regulatory pathways, and economic factors, an informed projection of this drug's market trajectory and pricing landscape can be articulated.
Drug Profile and Regulatory Context
The NDC 23155-0872 falls under the purview of the U.S. Food and Drug Administration (FDA) for marketing approval. Understanding its regulatory status—whether it is a new molecular entity, biosimilar, or an authorized generic—is vital for market positioning.
If the drug is recently approved or pending approval, market entry timelines and initial pricing are influenced by the competitive environment, exclusivity periods, and formulary considerations. The drug's therapeutic class—be it oncology, neurology, or infectious disease—significantly influences demand and pricing strategies.
Market Dynamics and Competitive Landscape
1. Therapeutic Area and Demand Drivers
The demand for pharmaceuticals hinges on disease prevalence, unmet clinical needs, and therapeutic differentiation. For instance, drugs targeting rare diseases or niche indications often command premium pricing due to limited competition; conversely, blockbusters in broad indications face intense competition and price compression.
2. Competitive Environment
From generic entrants to biosimilars and branded alternatives, the competitive landscape shapes market share and pricing. A novel mechanism of action or significant clinical advantage can justify higher price points, while biosimilars may drive prices downward.
3. Payer and Reimbursement Framework
Insurance coverage, formulary inclusion, and prior authorization requirements directly affect drug accessibility and revenue potential. Favorable formulary placement often correlates with higher sales volume and better margins.
4. Market Penetration Strategies
Pharmaceutical companies leverage targeted marketing, patient assistance programs, and strategic partnerships to accelerate adoption. Early access programs and key opinion leader engagement are instrumental in establishing market presence.
Pricing Factors and Projected Price Trends
1. Baseline Pricing Considerations
Initial pricing is influenced by manufacturing costs, R&D investment recovery, competitive pricing, and reimbursement expectations. For innovative drugs, launch prices often range from several thousand to tens of thousands of dollars per treatment course or annual dose.
2. Price Trajectory and Trends
-
Initial Launch Pricing (Years 1-2): Likely premium, reflecting novelty and exclusivity. If regulatory exclusivity or patent protections are in place, prices can sustain at higher levels for up to 12-20 years, depending on patent life and regulatory data exclusivity.
-
Market Entry of Generics/Biosimilars (Years 3-7): Expect significant price erosion—studies have shown generic versions reduce prices by 80-90% in some cases. The timeline depends on patent litigation and biosimilar approval pathways.
-
Long-term Pricing (Post-Patent): When generic or biosimilar competition saturates the market, prices stabilize at low marginal costs, often 20-30% of original branded prices, potentially impacting revenue projections.
3. Influencing External Factors
Regulatory policies, like price negotiation and importation laws, as well as inflation and supply chain effects, will impact long-term pricing. The recent legislative focus on drug pricing transparency and value-based pricing models may also influence future price adjustments.
Market Size and Revenue Projections
1. Estimating the Target Population
Prevalence data from CDC, WHO, or specialty societies can inform market size estimates. For rare diseases, the total addressable population may be in the thousands, constraining revenue but often enabling premium pricing. For widespread conditions, targeted therapies can realize substantial revenues.
2. Revenue Scenarios
-
Optimistic Scenario: Early market adoption, high reimbursement rates, and strong clinical differentiation lead to peak annual revenues in the hundreds of millions to over a billion dollars.
-
Moderate Scenario: Moderate uptake with some competition and pricing pressures yields annual revenues in the tens to low hundreds of millions.
-
Conservative Scenario: Delays due to regulatory hurdles or market resistance, with constrained sales, result in substantially lower revenues.
3. Market Share Projections
A typical new branded drug can secure 20-50% of the diagnosed/preferred patient population within 3-5 years, depending on formulary positioning and clinical advantages. Over time, generic/equivalent entry erodes share, but strategic positioning can prolong profitability.
Risk Factors and Uncertainties
-
Regulatory Delays or Denials: Can postpone market entry and impact projected revenue streams.
-
Pricing and Reimbursement Challenges: Economic and legislative shifts may cap prices, affecting margins.
-
Competitive Actions: Emergence of superior therapies or biosimilars could rapidly diminish market share.
-
Supply Chain and Manufacturing: Disruptions could affect availability and costs, influencing pricing stability.
Key Takeaways
-
Market entry strategy is critical. Early adoption, clinical differentiation, and payer engagement dictate pricing power and revenue upside.
-
Pricing will evolve over time. High initial prices are expected, cushioning early investment, with significant declines anticipated upon generic/biosimilar entry.
-
Regulatory landscape shapes projections. Patent protections, exclusivities, and legislative policies are pivotal in maintaining profitability.
-
Market size and unmet needs drive revenue potential. Precise epidemiological data must inform realistic projections.
-
Risk mitigation is essential. Continuous monitoring of regulatory, competitive, and reimbursement developments enhances strategic agility.
FAQs
1. What is the typical patent exclusivity period for a new drug like the one under NDC 23155-0872?
Patent protections generally last 20 years from filing, but effective market exclusivity often ranges from 8 to 12 years due to patent extensions, regulatory data exclusivities, and market dynamics.
2. How do biosimilars impact pricing projections for biologic drugs?
Biosimilars typically lead to substantial price reductions—by 20-50%—and can erode market share of original biologics after patent expiry, significantly impacting long-term revenues.
3. What are common hurdles in launching a new pharmaceutical product?
Regulatory approval delays, payer reimbursement challenges, competitive pressures, manufacturing issues, and market acceptance are primary hurdles.
4. How do legislative policies influence drug pricing?
Legislative initiatives—such as drug price negotiation programs, importation laws, and transparency mandates—can cap prices, impose rebates, or restrict pricing strategies, affecting profit margins.
5. When should a company consider transitioning from premium pricing to value-based pricing?
Once clinical data demonstrate comparative effectiveness, and reimbursement negotiations favor outcomes-based models, shifting toward value-based pricing can optimize long-term profitability.
Sources:
[1] U.S. Food and Drug Administration (FDA). Drug Approval and Patent Data.
[2] IQVIA. Market Dynamics and Pharmaceutical Pricing Reports.
[3] Congressional Budget Office (CBO). Price Trends and Market Impact Studies.
[4] GlobalData. Biosimilars and Generic Market Outlook.
[5] Centers for Disease Control and Prevention (CDC). Epidemiological Data.
More… ↓
